Novartis India Ltd

Novartis India Annual General Meeting

Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.

Novartis India Earnings Call Transcript: Key Takeaways

Novartis India transition to ChrysCapital ownership (70.68%), pivoting from a partner-led model to a direct, in-house commercial platform focusing on chronic therapies like cardiology and ophthalmology.

Novartis India Investor Presentation: Key Takeaways

Novartis India Limited (NIL) shifts to a direct-to-market model under new ownership by ChrysCapital, acquiring the 'Minipress' brand for ₹1,250 Cr and in-licensing an ophthalmic portfolio.

Novartis India Other Announcement

Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.

Novartis India Partnership

Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.

Value

₹10.00 Cr

Novartis India Business Update

Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.

Value

₹1,250 Cr

Novartis India Acquisition Worth ₹1,250 Cr

Novartis India acquired Minipress/Minipres trademarks and related IP from Pfizer for ₹1,250 Crore. The board approved and the asset purchase agreement was executed on September 7, 2026.

Value

₹1,250 Cr

Novartis India Annual General Meeting

Novartis India Limited submits its Annual Report for FY 2025-26 and notice for the 78th Annual General Meeting scheduled on September 24, 2026.

Novartis India Board Meeting Outcome

Novartis India's board approved adopting a new Memorandum of Association and a proposal to change the company's name, both subject to shareholder approval at the AGM.

Novartis India Other Announcement

This is the quarterly shareholding pattern filing for Novartis India Ltd as per SEBI regulations. No significant corporate event is disclosed in this submission.

Novartis India Business Update

Novartis India terminated its 2022 distribution agreement with Dr. Reddy's Laboratories, effective September 30, 2026. The company will now re-acquire exclusive product distribution and marketing rights.

Novartis India Board Meeting Outcome

Novartis India's Board approved the termination of a distribution agreement with Dr. Reddy's, alongside adopting new Articles, an ESOP 2026 plan, and the 78th AGM notice.

Novartis India Business Update

Novartis India executed a royalty-free license deed for the 'Tegrital' trademark. This agreement allows the company to manufacture and market the Tegrital pharmaceutical product range.

Novartis India Management Change

Novartis India announced a board reconstitution, appointing six new directors and accepting the resignations of seven directors and the company's Chief Financial Officer.

Novartis India Board Meeting Outcome

Novartis India Limited reconstituted its Audit, Nomination and Remuneration, and Corporate Social Responsibility committees following director appointments and resignations during its 246th Board Meeting.

Novartis India Promoter Selling (Off-Market)

Novartis AG sold its entire 70.68% stake (1,74,50,680 shares) in Novartis India Limited. The seller is reclassifying from promoter to public category following this divestment.

Novartis India Promoter Selling (Off-Market): ₹1,377 Cr

Novartis AG (promoter) sold its entire 70.68% stake, totaling 1,74,50,680 shares, in an off-market transaction valued at ₹1,376.89 Crore.

Value

₹1,377 Cr

Novartis India Promoter Reclassification

Novartis AG has formally reclassified from "Promoter" to "Public" shareholder category following its divestment and loss of control in Novartis India Limited.

Novartis India Merger & Restructuring

Novartis AG completed the sale of 17.45 million shares to WaveRise and ChrysCapital, triggering a change in control and reclassification of the promoter to public category.

Novartis India Capital Structure Change

WaveRise Investments and others disclosed a substantial acquisition of shares in Novartis India Limited. The acquirers have become part of the promoter group of the company.

Novartis India Q1 FY27 Results: Net Profit ₹32.2 Cr, Up 16.7% YoY

Novartis India Ltd reported revenue from operations of ₹103.8 Cr (+18.6% YoY) and net profit of ₹32.2 Cr (+16.7% YoY) for Q1 FY27.

Key figure

Net profit ₹32.2 Cr · +16.7% YoY

Novartis India Other Announcement

Novartis India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of shares across promoter and public categories.

Novartis India Open Offer: ₹552.5 Cr

Axis Capital issued a post-offer advertisement for the open offer of Novartis India Limited. The acquirers proposed a ₹552.50 Crore acquisition but accepted only 40 shares.

Value

₹552.5 Cr

Novartis India Board Meeting Date

Novartis India Ltd will hold a Board meeting on 23 July 2026. The meeting will consider the unaudited results for Q2 2026.

Novartis India Open Offer

Acquirers launched an open offer for Novartis India at INR 860.64 per share. Public shareholders can tender shares from June 11 to June 24, 2026.

Novartis India Open Offer: ₹552.5 Cr

WaveRise Investments and others launched a ₹552.50 Crore open offer for 26% of Novartis India. The offer price is set at ₹860.64 per equity share.

Value

₹552.5 Cr

Execution

10 working days

Novartis India Other Announcement

Novartis India Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no significant non-compliances noted.

Novartis India Annual General Meeting

Novartis India shareholders approved Ms. Gowree Gokhale's appointment as Independent Director for five years via postal ballot. The resolution passed with a 99.97% majority vote.

Execution

5 years

Novartis India Q4 FY26 Results: Net Profit ₹25.2 Cr, Down 14.0% YoY

Novartis India Ltd reported revenue from operations of ₹90.5 Cr (+7.9% YoY) and net profit of ₹25.2 Cr (-14.0% YoY) for Q4 FY26.

Key figure

Net profit ₹25.2 Cr · -14.0% YoY

Novartis India Financial Results

Novartis India approved its audited financial results for the year ended March 31, 2026. The board declared an unmodified audit opinion, signaling stable financial reporting standards.